Hyperion DeFi, Inc.
HYPDHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframePart of the healthcare sector, Hyperion DeFi, Inc. (HYPD) is listed under Biotechnology. The $42.6M market capitalization puts HYPD squarely in micro-cap range for its industry. It operates through two segments: Ophthalmic Technology and Digital Assets.
Market Cap
$42.6M
Beta
2.52
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-6.21
EPS (Fwd)
—
ROE
9.6%
ROA
-11.1%
Cash
$9.6M
Total Debt
$8.9M
Free CF
-$14.8M
52W Change
-63.8%
Annual Financials
Cash vs Debt
Where HYPD stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, HYPD finished 14.88% below its 150-day moving average ($3.36) and 15.38% below its 200-day moving average ($3.38). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is HYPD overbought or oversold?
At the October 20, 2026 close, HYPD's RSI(14) was 21.2, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $9.6M in cash comfortably exceeding the $8.9M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$14.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at 9.6%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
Hyperion DeFi, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing HYPD.